New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 3, 2013
06:42 EDTREGN, SNYRegeneron acquires full rights to two novel development programs from Sanofi
Regeneron Pharmaceuticals (REGN) announced that it has expanded its ophthalmology portfolio by acquiring full exclusive rights to two families of novel antibodies invented at Regeneron and previously included in Regeneron's antibody collaboration with Sanofi (SNY). Regeneron acquired full rights to antibodies targeting the PDGF, or platelet derived growth factor, family of receptors and ligands in ophthalmology and all other indications and to antibodies targeting the ANG2 receptor and ligand in ophthalmology. Antibodies to PDGF and ANG2 are currently in preclinical development for use in ophthalmology. With respect to PDGF antibodies, Regeneron will pay Sanofi $10M upfront, up to $40M in development milestone payments, and royalties on sales. With respect to ANG2 antibodies in ophthalmology, Regeneron will pay Sanofi $10M upfront, a potential $5M development milestone payment, and royalties on sales.
News For REGN;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
07:49 EDTREGNRegeneron reinstated with a Buy at BofA/Merrill
Subscribe for More Information
September 30, 2014
16:39 EDTSNYCMS discloses drug makers' payments to doctors, WSJ says
Subscribe for More Information
10:53 EDTREGN, SNYRegeneron dupilumab opportunity improved with new data, says Piper Jaffray
Piper Jaffray said it is increasingly optimistic about dupilumab's broad potential in allergic diseases following the Phase II data on chronic sinusitis with nasal polyps as well as prior data in atopic dermatitis and asthma. The firm views dupilumab as a potential blockbuster and reiterates its Overweight rating and $382 price target on Regeneron (REGN), which announced the data in partnership with Sanofi (SNY).
07:30 EDTSNYSachs Associates to hold a conference
14th Annual Biotech in Europe Forum for Global Partnering and Investment to be held in Basel, Switzerland on September 30-October 1.
05:16 EDTREGN, SNYRegeneron, Sanofi announce positive Phase 2 top-line dupilumab results
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps, or CSwNP, who did not respond to intranasal corticosteroids. In the study, dupilumab resulted in a statistically-significant improvement in the size of nasal polyps, as measured by endoscopic Nasal Polyp Score, the primary endpoint of the study. Statistically significant improvements in all secondary efficacy endpoints were also observed, including objective measures of sinusitis by CT scan, nasal air flow, and patient-reported symptoms. In a pre-specified exploratory analysis, dupilumab-treated patients who also had asthma demonstrated significant improvements in asthma control. The safety profile was consistent with previous studies. The most common AEs with dupilumab were injection site reactions, nasopharyngitis, oropharyngeal pain, epistaxis, headache and dizziness.
September 29, 2014
07:26 EDTREGNInforma Business Information to hold a conference
Subscribe for More Information
September 25, 2014
08:59 EDTREGNSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
September 24, 2014
17:01 EDTSNYMannKind announces closing of global licensing agreement with Sanofi
Subscribe for More Information
08:10 EDTSNYSanofi unit announces research collaboration
Subscribe for More Information
September 23, 2014
09:00 EDTSNYBofa/Merill special situations team to hold an analyst/industry conference call
Subscribe for More Information
September 22, 2014
07:21 EDTSNYEBD Group to hold a conference
Subscribe for More Information
05:17 EDTREGNRegeneron announces EYLEA injection approved for myopic CNV treatment in Japan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use